|
|
| Line 1: |
Line 1: |
| __NOTOC__
| |
| {{Urticaria}}
| |
| {{CMG}}
| |
|
| |
|
| ==Overview==
| |
|
| |
| ==Epidemiology and Demographics==
| |
| ===Incidence===
| |
| *The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
| |
| *In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
| |
|
| |
| ===Prevalence===
| |
| *The [[prevalence]] of [[urticaria|acute urticaria]] is approximately 12-23.5%. Although the real [[prevalence]] is estimated to be even more, since mild cases usually don't seek [[medicine|medical]] attention. <ref name="pmid14616095">{{cite journal| author=Zuberbier T| title=Urticaria. | journal=Allergy | year= 2003 | volume= 58 | issue= 12 | pages= 1224-34 | pmid=14616095 | doi=10.1046/j.1398-9995.2003.00327.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14616095 }} </ref><ref name="pmid5801331">{{cite journal| author=Champion RH, Roberts SO, Carpenter RG, Roger JH| title=Urticaria and angio-oedema. A review of 554 patients. | journal=Br J Dermatol | year= 1969 | volume= 81 | issue= 8 | pages= 588-97 | pmid=5801331 | doi=10.1111/j.1365-2133.1969.tb16041.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5801331 }} </ref>
| |
|
| |
| ===Case-fatality rate/Mortality rate===
| |
| *In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
| |
| *The case-fatality rate/mortality rate of [disease name] is approximately [number range].
| |
|
| |
| ===Age===
| |
| *Patients of all age groups may develop [[urticari]], nevertheless manifestations commonly affect [[patient|patients]] with 20-40 years old.<ref name="pmid24404388">{{cite journal| author=Losol P, Yoo HS, Park HS| title=Molecular genetic mechanisms of chronic urticaria. | journal=Allergy Asthma Immunol Res | year= 2014 | volume= 6 | issue= 1 | pages= 13-21 | pmid=24404388 | doi=10.4168/aair.2014.6.1.13 | pmc=3881394 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24404388 }} </ref>
| |
|
| |
| ===Race===
| |
| *There is no racial predilection to [disease name].
| |
| *[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
| |
| ===Gender===
| |
| *Females are more commonly affected by [[urticaria]] than males. The female to male ratio is approximately 2 to 1.<ref name="pmid24404388">{{cite journal| author=Losol P, Yoo HS, Park HS| title=Molecular genetic mechanisms of chronic urticaria. | journal=Allergy Asthma Immunol Res | year= 2014 | volume= 6 | issue= 1 | pages= 13-21 | pmid=24404388 | doi=10.4168/aair.2014.6.1.13 | pmc=3881394 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24404388 }} </ref>
| |
|
| |
| ===Region===
| |
| *The majority of [disease name] cases are reported in [geographical region].
| |
|
| |
| *[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
| |
|
| |
| ===Developed Countries===
| |
|
| |
| ===Developing Countries===
| |
|
| |
| ==References==
| |
| {{Reflist|2}}
| |
|
| |
| {{WH}}
| |
| {{WS}}
| |
| [[Category: (name of the system)]]
| |
|
| |
| ==References==
| |
| {{Reflist|2}}
| |
| {{WH}}
| |
| {{WS}}
| |
|
| |
| [[Category:Needs content]]
| |
| [[Category:Dermatology]]
| |
| [[Category:Allergology]]
| |
| [[Category:Immunology]]
| |
| [[Category:Emergency medicine]]
| |
| [[Category:Disease]]
| |